ESSA Pharma Revenue, Profits - EPIX Annual Income Statement

Add to My Stocks
$2.67 $0.33 (11%) EPIX stock closing price Sep 21, 2018 (Closing)

Fundamental analysis of EPIX stock involves analyzing its financial statements, apart from checking the ESSA Pharma stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. Like any other income statement, the EPIX income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue decline of 0 when compared to the same period in the past. One also needs to look at ESSA Pharma assets, operating expenses and ESSA Pharma free cash flow. The ESSA Pharma profit and loss statement shows revenue of $- for 2017. Revenue has decreased by 0 YOY for EPIX stock.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Oct - Sep2017201620152014
ESSA Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)----
ESSA Pharma Gross Profit
Research & Development Expense5.72M13.06M4.5M-
Selling General & Admin Expense5.92M6.58M5.05M1.16M
Income Before Depreciation Depletion Amortization-11.65M-19.64M-9.56M-1.81M
Depreciation Depletion Amortization----
Non Operating Income7.26M6.65M--
Interest Expense----
ESSA Pharma Pretax Income
Provision for Income Taxes----
Investment Gains Losses----
Other Income----
Income Before Extraordinaries & Disc Operations-4.72M-13.13M-8.79M-1.81M
Extraordinary Items & Discontinued Operations----
ESSA Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS1.46M1.35M--
Average Shares used to compute Basic EPS1.46M1.35M--
Income Before Nonrecurring Items-11.81M-19.71M-8.8M-
Income from Nonrecurring Items7.31M6.57M--
ESSA Pharma Earnings Per Share Basic Net
ESSA Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-8.00-14.60-9.60-
Preferred Dividends Acc Pd----
Dividends Common----
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.

It is very helpful to read a report on ESSA Pharma stock analysis. An investor must check the following items in an income statement:

  • Topline: A growing topline, as seen from the ESSA Pharma revenue chart, as isn't the case with ESSA Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of EPIX stock with its peers like BIOAF stock and CLGN stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-4.72M for EPIX stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the EPIX income statement, one can check the ESSA Pharma historical stock prices to check how the price has moved with time.

ESSA Pharma Income Statement - Key Financial Ratios